Anika Therapeutics, Inc. (ANIK) Balance Sheet

The shrinkage is equity-funded, not liability-funded: total liabilities actually fell from $55.2M to $46.2M over the window, so the asset base is being reduced through losses and capital return rather than distress. This matters because the earlier income statement work showed revenue recovering 15.6% in 2026Q2, yet the balance sheet has not re-expanded — suggesting the recovery has not yet translated into reinvestment. Investors should treat the 'improving top line' narrative as decoupled from balance-sheet momentum until asset levels stabilize.

Capex running below depreciation implies the fixed-asset base is being consumed faster than replenished, which may support short-term free cash flow but could constrain capacity or raise future replacement costs if volumes continue to recover. Goodwill at $7.8M is only 4% of assets, so impairment risk is not a material swing factor — a notably cleaner profile than many device peers carrying goodwill-heavy acquisitions. The asset intensity relative to peers such as Novocure or AtriCure reinforces that Anika's economics remain tied to utilization of its owned production infrastructure.

The retained-earnings decline of $64.5M roughly matches the scale of cumulative losses plus buybacks, which means capital return has proceeded even as operating cash generation turned negative in 2026 — a sequencing choice that may prove aggressive if losses persist. Prior analysis flagged $28M of stock-based compensation over the window, which mechanically supports book equity through additional paid-in capital while diluting per-share claims. On a per-share economic basis, the equity cushion likely looks thinner than the $137.3M headline suggests.

Absolute solvency is not in question — debt is modest at 0.17 D/E and well below peer levels such as Lantheus at 0.57 — so refinancing risk appears minimal based on reported figures. However, the direction of travel is the concern: cash has fallen in four of the last six quarters while working capital consumed roughly $23M in the first half of 2026 alone. If that working-capital drag proves structural rather than timing-driven, the liquidity buffer could tighten faster than the current ratio implies.